BioMarin Pharmaceutical (BMRN) Competitors $68.36 -0.37 (-0.53%) As of 02:21 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends BMRN vs. ALNY, BIIB, UTHR, INCY, NBIX, EXEL, EXAS, RGEN, HALO, and MDGLShould you be buying BioMarin Pharmaceutical stock or one of its competitors? The main competitors of BioMarin Pharmaceutical include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), Neurocrine Biosciences (NBIX), Exelixis (EXEL), Exact Sciences (EXAS), Repligen (RGEN), Halozyme Therapeutics (HALO), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "biotechnology" industry. BioMarin Pharmaceutical vs. Alnylam Pharmaceuticals Biogen United Therapeutics Incyte Neurocrine Biosciences Exelixis Exact Sciences Repligen Halozyme Therapeutics Madrigal Pharmaceuticals Alnylam Pharmaceuticals (NASDAQ:ALNY) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, community ranking, earnings, dividends, analyst recommendations, valuation and media sentiment. Is ALNY or BMRN more profitable? BioMarin Pharmaceutical has a net margin of 11.71% compared to Alnylam Pharmaceuticals' net margin of -12.37%. BioMarin Pharmaceutical's return on equity of 8.53% beat Alnylam Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Alnylam Pharmaceuticals-12.37% N/A -6.83% BioMarin Pharmaceutical 11.71%8.53%6.40% Do analysts rate ALNY or BMRN? Alnylam Pharmaceuticals presently has a consensus price target of $299.48, indicating a potential upside of 18.61%. BioMarin Pharmaceutical has a consensus price target of $93.81, indicating a potential upside of 36.49%. Given BioMarin Pharmaceutical's higher possible upside, analysts plainly believe BioMarin Pharmaceutical is more favorable than Alnylam Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alnylam Pharmaceuticals 1 Sell rating(s) 5 Hold rating(s) 19 Buy rating(s) 0 Strong Buy rating(s) 2.72BioMarin Pharmaceutical 0 Sell rating(s) 7 Hold rating(s) 16 Buy rating(s) 0 Strong Buy rating(s) 2.70 Which has higher earnings and valuation, ALNY or BMRN? BioMarin Pharmaceutical has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlnylam Pharmaceuticals$2.25B14.54-$278.16M-$2.17-116.36BioMarin Pharmaceutical$2.75B4.76$167.65M$2.2031.24 Does the MarketBeat Community prefer ALNY or BMRN? BioMarin Pharmaceutical received 429 more outperform votes than Alnylam Pharmaceuticals when rated by MarketBeat users. However, 76.20% of users gave Alnylam Pharmaceuticals an outperform vote while only 74.50% of users gave BioMarin Pharmaceutical an outperform vote. CompanyUnderperformOutperformAlnylam PharmaceuticalsOutperform Votes114376.20% Underperform Votes35723.80% BioMarin PharmaceuticalOutperform Votes157274.50% Underperform Votes53825.50% Does the media prefer ALNY or BMRN? In the previous week, BioMarin Pharmaceutical had 1 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 43 mentions for BioMarin Pharmaceutical and 42 mentions for Alnylam Pharmaceuticals. BioMarin Pharmaceutical's average media sentiment score of 0.95 beat Alnylam Pharmaceuticals' score of 0.40 indicating that BioMarin Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 19 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral BioMarin Pharmaceutical 11 Very Positive mention(s) 1 Positive mention(s) 15 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Do insiders & institutionals believe in ALNY or BMRN? 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are held by institutional investors. 1.5% of Alnylam Pharmaceuticals shares are held by company insiders. Comparatively, 1.9% of BioMarin Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has more risk and volatility, ALNY or BMRN? Alnylam Pharmaceuticals has a beta of 0.35, suggesting that its share price is 65% less volatile than the S&P 500. Comparatively, BioMarin Pharmaceutical has a beta of 0.28, suggesting that its share price is 72% less volatile than the S&P 500. SummaryBioMarin Pharmaceutical beats Alnylam Pharmaceuticals on 13 of the 18 factors compared between the two stocks. Get BioMarin Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BMRN vs. The Competition Export to ExcelMetricBioMarin PharmaceuticalPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.10B$6.99B$5.80B$9.11BDividend YieldN/A2.88%5.28%3.98%P/E Ratio41.166.1625.9119.13Price / Sales4.76315.42474.53119.58Price / Cash36.2675.0445.1138.24Price / Book2.616.547.655.12Net Income$167.65M$138.11M$3.18B$245.96M7 Day Performance5.98%-0.74%-0.49%-0.89%1 Month Performance9.92%-0.16%1.84%-0.51%1 Year Performance-22.37%-1.82%18.66%16.50% BioMarin Pharmaceutical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BMRNBioMarin Pharmaceutical4.9364 of 5 stars$68.37-0.5%$93.81+37.2%-22.5%$13.04B$2.85B31.103,401Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageALNYAlnylam Pharmaceuticals4.5256 of 5 stars$256.45-3.2%$299.43+16.8%+68.7%$33.08B$1.83B-97.882,100Analyst ForecastInsider TradeBIIBBiogen4.7769 of 5 stars$137.33-0.8%$211.96+54.3%-37.5%$20.01B$9.84B12.417,570Analyst ForecastUTHRUnited Therapeutics4.4129 of 5 stars$370.58+0.0%$382.08+3.1%+71.5%$16.55B$2.33B16.271,168Insider TradeINCYIncyte4.5814 of 5 stars$70.42+0.6%$75.59+7.3%+21.4%$13.57B$3.70B503.042,524NBIXNeurocrine Biosciences4.9754 of 5 stars$115.02-1.6%$166.90+45.1%-12.5%$11.65B$2.36B34.961,400Analyst DowngradeAnalyst RevisionGap UpEXELExelixis4.6803 of 5 stars$35.00+1.5%$37.24+6.4%+70.1%$10.00B$1.83B22.441,310Analyst UpgradeInsider TradeGap UpEXASExact Sciences4.671 of 5 stars$49.31-2.5%$72.76+47.6%-21.1%$9.13B$2.50B-42.146,600Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageRGENRepligen4.3262 of 5 stars$146.92+0.5%$182.91+24.5%-18.6%$8.23B$638.76M-397.071,783Earnings ReportAnalyst ForecastNews CoverageHALOHalozyme Therapeutics4.5001 of 5 stars$58.29-0.5%$60.89+4.5%+59.6%$7.42B$829.25M19.30390Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageMDGLMadrigal Pharmaceuticals3.3531 of 5 stars$337.20-4.1%$351.67+4.3%+52.8%$7.35BN/A-13.4490 Related Companies and Tools Related Companies ALNY Competitors BIIB Competitors UTHR Competitors INCY Competitors NBIX Competitors EXEL Competitors EXAS Competitors RGEN Competitors HALO Competitors MDGL Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BMRN) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | SponsoredTop Picks for Trump’s Pro-Crypto America10,000% Crypto Opportunities in 2025 27 of the brightest minds in crypto share exclusive intel… Crypto 101 Media | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioMarin Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioMarin Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
